Indeed, immunohistochemistry (IHC) staining of PD-L1 in tumor cells or immune cells is more frequently observed in responders to anti-PD-1/PD-L1 monoclonal antibody therapies[2-5,8]. This evidence concerns the gene CD274 and neoplasm.